| Today’s Big NewsNov 19, 2024 |
| By Zoey Becker The phase 3 successes pad the IL-23 blocker's case as J&J prepares to go against BMS' oral psoriasis treatment Sotyktu in a separate study. |
|
|
|
By James Waldron Delegates told Fierce that the mix of pharma and finance attendees is helping add to the popularity of the expanding Jefferies Healthcare Conference in London. |
By Nick Paul Taylor Incyte’s $750 million Escient Pharmaceuticals buyout has rapidly run into problems. Less than six months after closing the deal, Incyte has paused a key study over preclinical toxicology findings and axed another program altogether. |
Sponsored by Adaptive Biotechnologies Discover how minimal residual disease (MRD) assessment is accelerating multiple myeloma drug development through FDA's latest guidance. |
|
Explore the latest additions to the GS®️ expression toolbox and strategies for using these technologies to drive successful development of your molecule from discovery through to commercial supply. During this webinar, you’ll also hear about innovative methods for creating the next generation of cell expression systems. 
|
|
By Fraiser Kansteiner Across three doses tested in a phase 2 study, Lilly’s lipoprotein (a) inhibitor muvalaplin helped significantly reduce patients’ heightened levels of Lp(a)—a genetic risk factor for heart disease—versus placebo. The win bodes well for Lilly after AstraZeneca picked up an experimental in-class rival last month. |
Sponsored by Dell Technologies Head of Life Sciences Strategy Alex Long shares key insights and advice for IT professionals working to enable healthcare’s technology transformation. |
By Nick Paul Taylor A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to launch the first treatment for the relentless itching experienced by some patients. |
By Nick Paul Taylor Neurogene followed up a premarket setback to its Rett syndrome program Monday with a postmarket confirmation that development of another gene therapy has hit a wall. |
By Kevin Dunleavy As BridgeBio approaches its FDA target date for approval of TTR stabilizer acoramidis to treat the rare heart disease transthyretin amyloid cardiomyopathy, the company has presented more data indicating it can become a force in the indication. |
By Gabrielle Masson Regenxbio’s investigational gene therapy improved muscle function for patients with Duchenne muscular dystrophy in a phase 1/2 study. After discussions with the FDA, the biotech has launched a pivotal study and plans on filing for accelerated approval in 2026. |
By Darren Incorvaia After failing to impress investors a year ago with an initial look at phase 2 data of a psilocybin-derived compound in major depressive disorder (MDD), Cybin momentarily boosted their spirits with a longer-term analysis. Twelve months after two 16 mg doses of the drug, called CYB003, seven patients saw their scores improve on the Montgomery–Åsberg Depression Rating Scale. |
By Zoey Becker In a contrarian take offered by BMO Capital Markets' Evan Seigerman, the analyst said Robert F. Kennedy Jr. may not rock the boat as much as feared for the biopharma industry. |
By Gabrielle Masson,Annalee Armstrong,Darren Incorvaia,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Ben Adams Cardiometabolic disease biotech NeuroBo Pharmaceuticals is shaking up its corporate image with a complete rebrand. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we explore a neuroscientist's alleged misconduct and its impact on the future of neurodegenerative disease research. |
|
|---|
|
|
|
The future of gene therapy is here, but with it comes manufacturing constraints, supply chain issues, and regulatory questions. Join us on November 20 for the Fierce Cell and Gene Virtual Event. Register Now! 
|
|
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
Whitepaper Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
